Company United Therapeutics Corporation

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-12 EDT			5-day change	1st Jan Change
286.14 ^USD	+3.50%		-10.50%	-18.90%

06-10	Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	MT
06-10	Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	RE

Business description: United Therapeutics Corporation

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Number of employees: 1,305

Sales by Activity: United Therapeutics Corporation

Fiscal Period: December	2020	2021	2022	2023	2024
Pharmaceuticals	1.48B	1.69B	1.94B	2.33B	2.88B

See all business segments

Geographical breakdown of sales: United Therapeutics Corporation

Fiscal Period: December	2020	2021	2022	2023	2024
United States	1.41B	1.56B	1.81B	2.2B	2.74B
Rest of World	71.2M	121M	122M	125M	138M

See all geographic segments

Executive Committee: United Therapeutics Corporation

Manager	Title	Age	Since
Martine Rothblatt CEO	Chief Executive Officer	70	1996-06-25
Michael Benkowitz PSD	President	53	2016-06-25
James Edgemond DFI	Director of Finance/CFO	57	2015-03-12
Dewey Steadman IRC	Investor Relations Contact	-	2018-12-31
Paul Mahon LAW	General Counsel	61	1996-06-25

See UNITED THERAPEUTICS CORPORATION governance

Composition of the Board of Directors: United Therapeutics Corporation

Director	Title	Age	Since
Raymond Kurzweil BRD	Director/Board Member	77	2001-12-31
Martine Rothblatt CHM	Chairman	70	1996-06-25
Louis Sullivan BRD	Director/Board Member	91	2001-12-31
Raymond Dwek BRD	Director/Board Member	83	2001-12-31
Christopher Patusky BRD	Director/Board Member	61	2002-10-23
Christopher Causey BRD	Director/Board Member	62	2002-12-31
Richard Giltner BRD	Director/Board Member	61	2009-04-28
Tommy Thompson BRD	Director/Board Member	82	2009-12-31
Judy Olian BRD	Director/Board Member	73	2015-06-25
Nilda Mesa BRD	Director/Board Member	65	2018-10-30

Composition of the Board of Directors

Shareholders: United Therapeutics Corporation

Name	Equities	%	Valuation
BlackRock Advisors LLC 10.98 %	4,929,498	10.98 %	1 572 M $
Vanguard Fiduciary Trust Co. 9.924 %	4,457,135	9.924 %	1 421 M $
Avoro Capital Advisor LLC 5.956 %	2,675,000	5.956 %	853 M $
STATE STREET CORPORATION 4.967 %	2,230,708	4.967 %	711 M $
Renaissance Technologies LLC 4.691 %	2,106,992	4.691 %	672 M $

List of UNITED THERAPEUTICS CORPORATION shareholders

Holdings: United Therapeutics Corporation

Name	Equities	%	Valuation
CELULARITY INC. 3.33%	796,885	3.33%	1,681,427 $

Company details: United Therapeutics Corporation

United Therapeutics Corp.

1000 Spring Street

20910, Silver Spring

+301 608 9292

http://www.unither.com

address United Therapeutics Corporation(UTHR)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
UNITED THERAPEUTICS CORPORATION	+3.50%	-10.50%	+1.52%	+29.68%	12.91B
ELI LILLY AND COMPANY	+0.42%	+6.05%	-6.37%	+173.40%	729B
JOHNSON & JOHNSON	+0.90%	+1.95%	+7.74%	-9.21%	377B
NOVO NORDISK A/S	+1.89%	+7.80%	-46.04%	+37.26%	358B
ABBVIE INC.	+0.48%	+2.64%	+15.85%	+34.37%	340B
ROCHE HOLDING AG	-0.64%	+0.86%	+10.05%	-12.53%	269B
NOVARTIS AG	-0.43%	+0.57%	+3.58%	+17.94%	236B
ASTRAZENECA PLC	-0.21%	+2.07%	-11.19%	+12.56%	232B
MERCK & CO., INC.	+1.87%	+5.41%	-37.16%	-6.15%	205B
AMGEN INC.	+1.88%	+3.55%	-1.26%	+23.87%	160B
Average	+0.28%	+2.38%	-6.33%	+30.12%	291.91B
Weighted average by Cap.	-0.17%	+4.14%	-6.74%	+52.98%